You are here

Article Text

Article menu
Download PDFPDF
Viewpoint
New approach to testing treatments for osteoarthritis: FastOA
  1. David Felson1,
  2. Martin K Lotz2,
  3. Yuxuan Jin3,
  4. Morgan Jones4,
  5. Jason S Kim5,
  6. Kurt Spindler3
  1. 1 Boston University School of Medicine, Boston, Massachusetts, USA
  2. 2 Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA
  3. 3 Cleveland Clinic Foundation, Cleveland, Ohio, USA
  4. 4 Brigham and Women's Hospital, Boston, Massachusetts, USA
  5. 5 Arthritis Foundation, Atlanta, Georgia, USA
  1. Correspondence to Professor David Felson, Boston University School of Medicine, Boston, MA 02118, USA; dfelson{at}bu.edu

Abstract

Animal models of post traumatic osteoarthritis have shown many promising treatments for disease, but human trials have mostly failed to identify effective treatments. This viewpoint suggests that the frequent failure of drug and treatment development in osteoarthritis is due, in part, to the advanced stage of disease of patients in trials and suggests that mirroring the animal model approach might be more successful. It suggests a path forward by enriching trial enrollees with those likely to develop post traumatic OA quickly.

  • Osteoarthritis
  • Orthopedic Procedures
  • Therapeutics

Data availability statement

The MOON data can be requested from Dr Spindler or Dr Jones.

https://doi.org/10.1136/ard-2023-224675

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Data availability statement

    The MOON data can be requested from Dr Spindler or Dr Jones.

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Twitter @david_felson

    • Contributors Drafting of manuscript: DF. Collecting data presented: MJ and KS. Editing and review of manuscript: MKL, YJ, MJ, JSK and KS. Analysis of data: YJ. Final approval of manuscript: DF, MKL, YJ, MJ, JSK and KS.

    • Funding Supported by the Arthritis Foundation and by NIH P30 AR072571.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Not commissioned; externally peer reviewed.